Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors

Journal of Clinical Virology

Volumn 35, Issue 4, 2006, Pages 414-419

  Torti, Carlo ^a   Uccelli, Maria Cristina ^a   Quiros Roldan, Eugenia ^a   Gargiulo, Franco ^b   Tirelli, Valeria ^a   Lapadula, Giuseppe ^a   Regazzi, Mario ^c   Pierotti, Piera ^d   Tinelli, Carmine ^c   Luca, Andrea De ^e   Patroni, Andrea ^a,c   Manca, Nino ^b   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

HIV resistance; Inhibitory quotient; Lopinavir; Pharmacokinetics; Virological response

Indexed keywords

DIDANOSINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; PREDICTIVE VALUE OF TESTS; PYRIMIDINONES; RNA, VIRAL; SALVAGE THERAPY;

EID: 33644637513     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2005.10.001     Document Type: Article

References (13)

1. D. Breilh, I. Pellegrin, A. Rouzes, K. Berthoin, F. Xuereb, and H. Budzinski Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study) AIDS 18 2004 1305 1310
2. A. Castagna, N. Gianotti, L. Galli, A. Danise, H. Hasson, and E. Boeri The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects with a lopinavir/ritonavir- containing regimen Antivir Ther 9 2004 537 543
3. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(17):1-19.
4. D. Gonzalez de Requena, O. Gallego, L. Valer, I. Jimenez-Nacher, and V. Soriano Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient AIDS Res Hum Retroviruses 20 2004 275 278
5. A. Hsu, J. Isaacson, S. Brun, B. Bernstein, W. Lam, and R. Bertz Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients Antimicrob Agents Chemother 47 2003 350 359
6. V.A. Johnson, F. Brun-Vezinet, B. Clotet, B. Conway, D.R. Kuritzkes, and D. Pillay Update of the drug resistance mutations in HIV-1 Top HIV Med 13 2005 51 57
7. D.J. Kempf, J.D. Isaacson, M.S. King, S.C. Brun, Y. Xu, and K. Real Identification of genotype changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients J Virol 75 2001 7462 7469
8. A.G. Marcelin, I. Cohen-Codar, M.S. King, P. Colson, E. Guillevic, and D. Descamps Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor experienced patients Antimicrob Agents Chemother 49 2005 1720 1726
9. M.J. Molina, A.G. Marcelin, J. Pavie, L. Heripret, C.M. De Boever, and M. Troccaz Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial J Infect Dis 191 2005 840 847
10. N.T. Parkin, C.M. Chappey, and C.J. Petropoulos Improving lopinavir genotype algorithm through phenotype correlation: novel mutation patterns and amprenavir cross-resistance AIDS 17 2003 955 961
11. C. Torti, E. Quiros-Roldan, W. Keulen, L. Scudeller, S. Lo Caputo, and C. Boucher Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients J Infect Dis 188 2003 194 201
12. C. Torti, E. Quiros-Roldan, M. Regazzi, A. De Luca, F. Mazzotta, and A. Antinori A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistence interpretation with or without concentration-controlled intervention: the resistance and dosage adapted regimens (RADAR) study Clin Infect Dis 40 2005 1828 1836
13. D. Wang, and B. Larder Enhanced prediction of lopinavir resistance from genotype by use of artificial neural network J Infect Dis 188 2003 653 660